Regulatory Strategy & Compliance
Navigate the complexities of EU MDR, FDA, and global regulatory frameworks with a clear strategy that accelerates market access and minimizes compliance risk.
Overview
The global medical device regulatory landscape has undergone a fundamental transformation. The EU MDR and IVDR have replaced the legacy directive framework with significantly more demanding requirements for clinical evidence, post-market surveillance, and technical documentation. Simultaneously, the FDA continues to evolve its review processes and expectations for submissions. Manufacturers face the challenge of not just meeting these requirements, but developing a coherent regulatory strategy that optimizes time-to-market across multiple jurisdictions without duplicating effort or creating conflicting documentation.
Swiss MPC provides strategic regulatory consulting that goes beyond simple compliance checklists. We help medical device manufacturers identify the most efficient regulatory pathway for each target market, develop comprehensive regulatory roadmaps with realistic timelines and resource requirements, and build the technical and clinical evidence packages needed to satisfy regulators and notified bodies. Our consultants bring direct experience with the major EU notified bodies, the FDA review divisions, and regulatory authorities across Asia and the Middle East.
Our regulatory strategy work begins with a thorough assessment of your device, its intended use, and your commercial objectives. We then map the applicable regulatory requirements across all target markets, identify the critical path activities, and develop a phased plan that sequences submissions for maximum efficiency. For manufacturers navigating the EU MDR transition, we provide specialized expertise in gap analysis, re-classification assessment, and transition planning to ensure continued market access throughout the certification timeline.
Whether you are bringing a novel device to market for the first time, transitioning legacy devices from the MDD to the EU MDR, or expanding into new geographic markets, Swiss MPC delivers the regulatory intelligence and strategic planning needed to make informed decisions, avoid common pitfalls, and achieve market access on schedule. Our track record includes successful submissions across all device classes and a wide range of therapeutic areas including cardiovascular, orthopedic, in vitro diagnostic, dental, and software-based medical devices.
Regulatory Challenges Facing Medical Device Manufacturers
EU MDR Transition Complexity
The transition from the Medical Devices Directive (MDD 93/42/EEC) to the EU MDR 2017/745 represents the most significant regulatory change in the European medical device market in decades. Manufacturers must re-classify devices under new rules, significantly expand clinical evidence including PMCF plans and clinical evaluation reports, enhance post-market surveillance systems, and navigate notified body capacity constraints — all while maintaining existing CE certificates and uninterrupted market access.
Regulatory Pathway Uncertainty
Selecting the wrong regulatory pathway wastes time and resources. Choosing between a 510(k) and a De Novo request, determining whether clinical investigation data is needed for EU MDR conformity assessment, or assessing whether a device falls under MDR or IVDR jurisdiction requires deep understanding of current regulatory interpretations, recent precedent, and evolving agency guidance. Errors in pathway selection can delay market entry by 12-24 months.
Notified Body Capacity and Expectations
The EU MDR significantly reduced the number of designated notified bodies while simultaneously increasing the volume and complexity of conformity assessments required. Manufacturers face extended review timelines, more demanding documentation requests, and evolving interpretive expectations from notified bodies that are themselves adapting to the new regulation. Proactive notified body management and early engagement have become critical success factors.
Multi-Market Registration Divergence
No two regulatory frameworks are identical, and the divergence between EU, FDA, and other major markets creates significant complexity for manufacturers pursuing global market access. Different classification systems, varying clinical evidence requirements, distinct labeling and language obligations, and unique submission formats mean that a single regulatory dossier cannot serve all markets. Strategic planning is needed to maximize data reuse while satisfying market-specific requirements.
Evolving Regulatory Expectations
Regulatory requirements are not static. New guidance documents, MDCG position papers, FDA draft guidances, and evolving standards continuously reshape expectations. Manufacturers that treat regulatory compliance as a one-time exercise rather than an ongoing discipline risk non-compliance and market disruption. A systematic approach to regulatory intelligence and horizon scanning is essential to stay ahead of changes that affect your device portfolio.
Our Regulatory Strategy Approach
Device and Portfolio Assessment
We begin with a comprehensive assessment of your device or product portfolio, including intended use analysis, device classification under all target regulatory frameworks (EU MDR rules, FDA product codes, and international equivalents), identification of applicable standards and guidance documents, and review of any existing regulatory history including prior submissions, certifications, and post-market data. This assessment provides the factual foundation for all strategic decisions.
Regulatory Pathway Identification and Evaluation
For each target market, we identify all viable regulatory pathways and evaluate them against your commercial timeline, available data, and resource constraints. This includes CE marking conformity assessment routes under EU MDR (including the role of notified bodies for different device classes), FDA submission types (510(k), De Novo, PMA, HDE), and equivalent pathways in other jurisdictions. We provide a clear recommendation with supporting rationale and risk assessment for each pathway option.
Regulatory Roadmap Development
We develop a detailed regulatory roadmap that sequences all activities across target markets, identifying critical path items, dependencies between workstreams, and key decision points. The roadmap includes realistic timelines based on current agency and notified body review periods, resource requirements for each phase, and contingency plans for common delays. This becomes your operational planning tool for the entire regulatory program.
Submission Strategy and Dossier Planning
We define the content, structure, and evidence requirements for each regulatory submission, maximizing data reuse across markets. For EU MDR, this means planning the technical file per Annex II/III with clinical evaluation, risk management, and post-market surveillance integration. For FDA, this includes developing the submission strategy (substantial equivalence arguments, predicate selection, clinical study design if required) and pre-submission meeting planning to align expectations with the reviewing division.
Regulatory Authority and Notified Body Engagement
We support direct engagement with regulatory authorities and notified bodies, including preparation for and participation in FDA pre-submission meetings, notified body application processes, and conformity assessment interactions. Our experience with major notified bodies and FDA review divisions allows us to anticipate likely questions, prepare robust responses, and manage the review process efficiently to minimize delays and information requests.
Ongoing Regulatory Intelligence and Lifecycle Management
Regulatory strategy does not end at initial market authorization. We provide ongoing regulatory intelligence covering new guidance documents, MDCG papers, standard revisions, and enforcement trends relevant to your device portfolio. We also support lifecycle regulatory activities including significant change assessments, periodic safety update reports, and renewal or recertification planning to ensure uninterrupted market access throughout the commercial lifecycle.
Regulatory Strategy Deliverables
- Regulatory assessment report with device classification analysis across target markets
- Regulatory pathway evaluation with recommendation and risk assessment
- Multi-market regulatory roadmap with timelines, milestones, and resource requirements
- Gap analysis report for EU MDR transition (legacy devices)
- Submission strategy document with dossier outlines and evidence requirements
- Standards applicability matrix mapping device to all applicable standards and guidances
- Pre-submission meeting briefing package (FDA) or notified body application support
- Regulatory correspondence management and authority interaction support
- Classification rule determination and justification documentation
- Regulatory change impact assessment templates and procedures
- Regulatory intelligence monitoring reports tailored to your device portfolio
Applicable Standards & Regulations
EU MDR 2017/745
The European Medical Devices Regulation establishing the legal framework for placing medical devices on the EU market. Introduces stricter classification rules, enhanced clinical evidence requirements, mandatory post-market surveillance, the EUDAMED database, and UDI obligations. Replaced the Medical Devices Directive (MDD 93/42/EEC) and Active Implantable Medical Devices Directive (AIMDD 90/385/EEC).
EU IVDR 2017/746
The European In Vitro Diagnostic Regulation replacing the IVDD 98/79/EC. Introduces a risk-based classification system (Classes A-D) aligned with GHTF principles, significantly increasing the number of IVDs requiring notified body involvement. Imposes enhanced performance evaluation requirements, clinical evidence expectations, and post-market performance follow-up obligations.
FDA 21 CFR Parts 800-1299
The body of US federal regulations governing medical devices, including establishment registration (Part 807), premarket notification 510(k) (Part 807 Subpart E), premarket approval PMA (Part 814), investigational device exemptions (Part 812), quality system regulation (Part 820), and medical device reporting (Part 803). Together, these regulations define the FDA regulatory framework for medical device manufacturers.
IMDRF Guidance Documents
The International Medical Device Regulators Forum publishes guidance documents on regulatory convergence topics including software as a medical device (SaMD), unique device identification (UDI), adverse event terminology, and regulatory authority assessment. IMDRF guidances increasingly influence national regulatory frameworks and provide a common reference point for multi-market strategies.
ISO 13485:2016
Quality management systems for medical devices — requirements for regulatory purposes. While primarily a QMS standard, ISO 13485 is fundamental to regulatory strategy because most regulatory frameworks require or recognize it as the basis for quality management. EU MDR harmonized standards reference it, and MDSAP audits are conducted against its requirements.
MEDDEV and MDCG Guidance Documents
Guidance documents issued by the European Commission Medical Device Coordination Group (MDCG, replacing MEDDEV guidances). These provide interpretive guidance on EU MDR and IVDR implementation, covering topics such as clinical evaluation (MDCG 2020-13), classification (MDCG 2021-24), and transitional provisions. While not legally binding, they represent the expected interpretation of regulatory requirements by notified bodies and competent authorities.
FDA Guidance Documents
The FDA publishes guidance documents that describe the agency current expectations for regulatory submissions, including content requirements for 510(k)s, clinical study design considerations, and cybersecurity pre-market expectations. While not legally binding, these guidances represent the FDA review divisions current thinking and significantly influence submission strategy and content planning.
MDSAP (Medical Device Single Audit Program)
A harmonized audit program recognized by regulatory authorities in the US, Canada, Australia, Japan, and Brazil. MDSAP audits assess a manufacturer quality management system against the requirements of all participating regulatory authorities in a single audit, providing an efficient mechanism for demonstrating compliance across multiple markets simultaneously.
Frequently Asked Questions
Related Services
Technical Documentation & CE Marking
Technical files, Design History Files, EU MDR/IVDR submissions, and FDA 510(k)/PMA
Learn moreClinical Affairs
Clinical Evaluation Reports, literature reviews, PMCF planning, and data collection
Learn moreMDR for Asia & Middle East
NMPA, PMDA, CDSCO, MFDS, SFDA, and MOHAP regulatory transition support
Learn moreReady to Accelerate Your Regulatory Compliance?
Schedule a free consultation with our senior regulatory experts